Hip
Senior Member
- Messages
- 18,148
One thing that occurred to me is that the Staphypan vaccine may have opposing effects depending on whether or not an individual has a Staphylococcus aureus infection in their body.
This is because if the patient does have a Staphylococcus aureus infection somewhere in their body, presumably they are going to be making antibodies to Staphylococcus alpha toxin, and antibodies to the other Staphylococcus toxins like enterotoxin B.
Now, when you inject the Staphypan vaccine, via the immune response to the alpha toxoid and enterotoxin B toxoid in the vaccine, this will boost levels of antibodies and against alpha toxin and enterotoxin B, which will have the effect of reducing Staphylococcus bacterial infection-derived alpha toxin and enterotoxin B levels in the blood (as the alpha toxin and enterotoxin B will be neutralized by the antibodies).
So the overall result of vaccination is a temporary increase in alpha toxoid levels and enterotoxin B toxoid levels just after the Staphypan vaccine injection, followed by a reduction in Staphylococcus bacterial infection-derived alpha toxin and enterotoxin B levels as a result of the boosted antibody response.
So that's what will happen in a patient that has a Staphylococcus aureus infection in their body. Apparently 20% of the population have Staphylococcus aureus on their skin, and 30% have this bacterium in their nose. 1 And 20% of the population have Staphylococcus aureus in the gut, and a further 9% have MRSA in their gut. 1 I know that I have Staphylococcus aureus in my gut, as I tested positive for this in a digestive stool analysis test.
However, if we consider people who do not have Staphylococcus aureus infections anywhere in their body, then in these people, the vaccine will have a different effect. As before you will get a temporary increase in alpha toxoid levels and enterotoxin B toxoid levels just after the Staphypan vaccine injection, but then nothing further after that. There will be no effects on alpha toxin and enterotoxin B, because a person without a Staphylococcus aureus infection will not have these two toxins in their blood.
So one possibility is that the ME/CFS-ameliorating effects of Staphypan are mediated directly by the effects of the alpha toxoid and enterotoxin B toxoid acting on receptors, etc. Another possibility is that these ME/CFS-ameliorating effects derive from the antibody boosting effects of the vaccine, which act to reduce Staphylococcus bacterial infection-derived alpha toxin and enterotoxin B levels in the blood.
This is because if the patient does have a Staphylococcus aureus infection somewhere in their body, presumably they are going to be making antibodies to Staphylococcus alpha toxin, and antibodies to the other Staphylococcus toxins like enterotoxin B.
Now, when you inject the Staphypan vaccine, via the immune response to the alpha toxoid and enterotoxin B toxoid in the vaccine, this will boost levels of antibodies and against alpha toxin and enterotoxin B, which will have the effect of reducing Staphylococcus bacterial infection-derived alpha toxin and enterotoxin B levels in the blood (as the alpha toxin and enterotoxin B will be neutralized by the antibodies).
So the overall result of vaccination is a temporary increase in alpha toxoid levels and enterotoxin B toxoid levels just after the Staphypan vaccine injection, followed by a reduction in Staphylococcus bacterial infection-derived alpha toxin and enterotoxin B levels as a result of the boosted antibody response.
So that's what will happen in a patient that has a Staphylococcus aureus infection in their body. Apparently 20% of the population have Staphylococcus aureus on their skin, and 30% have this bacterium in their nose. 1 And 20% of the population have Staphylococcus aureus in the gut, and a further 9% have MRSA in their gut. 1 I know that I have Staphylococcus aureus in my gut, as I tested positive for this in a digestive stool analysis test.
However, if we consider people who do not have Staphylococcus aureus infections anywhere in their body, then in these people, the vaccine will have a different effect. As before you will get a temporary increase in alpha toxoid levels and enterotoxin B toxoid levels just after the Staphypan vaccine injection, but then nothing further after that. There will be no effects on alpha toxin and enterotoxin B, because a person without a Staphylococcus aureus infection will not have these two toxins in their blood.
So one possibility is that the ME/CFS-ameliorating effects of Staphypan are mediated directly by the effects of the alpha toxoid and enterotoxin B toxoid acting on receptors, etc. Another possibility is that these ME/CFS-ameliorating effects derive from the antibody boosting effects of the vaccine, which act to reduce Staphylococcus bacterial infection-derived alpha toxin and enterotoxin B levels in the blood.